Impact of glucose metabolism in postnatal cardiomyocytes
Ontology highlight
ABSTRACT:
PROVIDER: PRJNA612444 | ENA |
REPOSITORIES: ENA
Dataset's files
| Action | DRS | |||
|---|---|---|---|---|
| SRR11302200.fastq.gz | Fastqsanger.gz | |||
| SRR11302201.fastq.gz | Fastqsanger.gz | |||
| SRR11302202.fastq.gz | Fastqsanger.gz | |||
| SRR11302203.fastq.gz | Fastqsanger.gz | |||
| SRR11302204.fastq.gz | Fastqsanger.gz |
Items per page: 5 1 - 5 of 12 |
Similar Datasets
Project description:We report RNA sequencing data from the postnatal cardiac myocytes of the wild type and Glucose transporter 1 (Glut1) overexpressed mouse
2021-03-01 | GSE146924 | GEO
Project description:During development the fetal heart undergoes a rapid and dramatic transition to adult function through transcriptional and post-transcriptional mechanisms, including alternative splicing (AS). We performed deep RNA-sequencing for high-resolution analysis of transcriptome changes during postnatal mouse heart development using RNA from ventricles and freshly isolated cardiomyocytes (CM) and cardiac fibroblasts (CF). Extensive changes in gene expression and AS occur primarily between postnatal days 1 and 28. CM and CF showed reciprocal regulation of gene expression during postnatal development reflecting differences in proliferative capacity, cell adhesion functions, and mitochondrial metabolism. We found that AS plays a novel role in vesicular trafficking and membrane organization during postnatal CM development. Interestingly, these AS transitions are enriched among targets of two RNA-binding proteins, Celf1 and Mbnl1, which undergo developmentally regulated change in expression. Vesicular traffic genes affected by AS during normal development where Celf1 is down-regulated, showed a reversion to neonatal AS patterns when Celf1 was over-expressed in adults. RNA-seq was performed in RNA samples of ventricles, cardiomyocytes or cardiac fibroblast at different developmental stages; embryonic day 17, postnatal day (PN) 1, 10, 28 and 90 for ventricles, PN1-3, PN28 and PN60 for cardiac fibroblasts, and PN1-2, PN30, and PN67 for cardiomyocytes
2014-04-16 | E-GEOD-49906 | biostudies-arrayexpress
Project description:Energy metabolism is a key aspect of cardiomyocyte biology. Human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CM) are a promising tool for biomedical application, but they are immature and have not undergone metabolic shift related to early postnatal development. Cultivation of hiPSC-CM in 3D engineered heart tissue (EHT) format leads to morphological maturation. This study compared the mitochondrial and metabolic state of hiPSC-CM in standard 2D culture and the EHT format and determined the influence of contractile activity. HiPSC-CM in EHTs showed ~2-fold higher number of mitochondria (electron microscopy), mitochondrial mass (mitotracker), DNA (Mt-ND1, Mt-ND2), and protein abundance (proteome) than in 2D culture. While hiPSC-CM exhibited the principal ability to use glucose, lactate and fatty acids as energy substrates irrespective of culture format, hiPSC-CM in 3D performed more oxidation of glucose, lactate and fatty acid, and less anaerobic glycolysis. The increase in mitochondrial mass and DNA in 3D was diminished by pharmacological inhibition of contractile force, suggesting that contractile work participates in mitochondrial development hiPSC-CM. In conclusion, contractile work in the EHT format contributes to metabolic maturation of hiPSC-CM.
2018-03-06 | PXD008205 | Pride
Project description:During development the fetal heart undergoes a rapid and dramatic transition to adult function through transcriptional and post-transcriptional mechanisms, including alternative splicing (AS). We performed deep RNA-sequencing for high-resolution analysis of transcriptome changes during postnatal mouse heart development using RNA from ventricles and freshly isolated cardiomyocytes (CM) and cardiac fibroblasts (CF). Extensive changes in gene expression and AS occur primarily between postnatal days 1 and 28. CM and CF showed reciprocal regulation of gene expression during postnatal development reflecting differences in proliferative capacity, cell adhesion functions, and mitochondrial metabolism. We found that AS plays a novel role in vesicular trafficking and membrane organization during postnatal CM development. Interestingly, these AS transitions are enriched among targets of two RNA-binding proteins, Celf1 and Mbnl1, which undergo developmentally regulated change in expression. Vesicular traffic genes affected by AS during normal development where Celf1 is down-regulated, showed a reversion to neonatal AS patterns when Celf1 was over-expressed in adults.
2014-04-16 | GSE49906 | GEO
Project description:Analysis of human iPS-derived cardiomyocytes exposed to glucose, endothelin-1 and cortisol in vitro. Treatment produces a surrogate diabetic cardiomyopathic phenotype. Results provide insight into the pathways regulated by the treatment in the cardiomyocyte. The RNA for each vehicle-control treated and glucose endothelin cortisol treated iPS derived cardiomyocytes from 4 replicate samples, were extracted and hybridized to 8 individual human HG-U133 Plus2.0 Affymetrix microarray gene chips, whereby each chip represented the expression profile for one cell culture at 2 days.
2014-10-10 | E-GEOD-62203 | biostudies-arrayexpress
Project description:Myelination is one of the final milestones of post-natal brain development in rodent and man. Oligodendrocytes, the myelinating glia of the CNS, are differentiated from proliferative progenitor cells called OPCs. Local and systemic signals act on OPCs to promote their proliferation and survival in the developing forebrain before growth arrest and differentiation. During this period, altricial mammals, like rodent, experience a dramatic shift in nutrient source (e.g., maternal blood or milk) and composition (e.g., carbohydrate or fatty acid). The influence of metabolism on neural cells is of growing interest, but how metabolic changes in the early postnatal brain impact OPC dynamics remains poorly understood. Here we show that a glucose oscillation in developing forebrain is detectable by MALDI MS imaging and correlates with a temporal and region-specific transition of OPCs from proliferation to differentiation. In dorsal cortex and white matter regions, glucose levels decline in the second postnatal week during a critical window when OPCs slow proliferation and begin differentiation. In ventral regions we observe continually elevated glucose and OPCs persist in a proliferative state, thereby suggesting that glucose availability serves as a local signal promoting progenitor expansion, or cell cycle exit and differentiation, in early brain. When OPCs are cultured in low glucose, we detect glucose-responsive histone acetylation changes and a transcriptional signature of cell cycle exit and differentiation. Mechanistically, we link the activity of the metabolic enzyme ATP citrate lyase, which converts glucose-derived citrate to the central metabolite acetyl-CoA, to acetylation and proliferation dynamics downstream of glucose availability in cultured cells. Pharmacological inhibition or genetic deletion of ACLY in cultured OPCs results in reduced histone acetylation and levels of cell cycle related transcripts, and reduced proliferation, supporting the hypothesis that glucose bioavailability influences OPC dynamics via ACLY. A transgenic animal model of conditional ACLY deletion in OPCs timed to the period of high glucose availability in brain results in decreased histone acetylation and growth-arrest leading to a depletion of the oligodendrocyte pool and hypomyelination. Finally, we link the emergence of ketone bodies in brain to the period of reduced glucose availability and show that alternative sources of acetyl-CoA that bypass glucose rescue Acly-/- OPC viability. Our results support a temporal-metabolic model centered on glucose availability in the timing of OPC growth arrest, and that alternative substrates of acetyl-CoA such as ketone body serve as a metabolic bridge during glucose fluctuations to promote oligodendrocyte survival and differentiation.
2025-10-02 | GSE278709 | GEO
Project description:Background: The targeted ERBB2 therapy, trastuzumab, has had a tremendous impact on management of patients with HER2+ breast cancer, leading to development and increased use of further HER2 targeted therapies. The major clinical side effect is cardiotoxicity but the mechanism is largely unknown. On the basis that gene expression is known to be altered in multiple models of heart failure, we examined differential gene expression of iPSC derived cardiomyocytes treated at day 11 with the ERBB2 targeted monoclonal antibody, trastuzumab for 48 hours and the small molecule tyrosine kinase inhibitor of EGFR and ERBB2. Methods: Transcriptome sequencing was performed on four replicates from each group (48 hours untreated, 48 hours trastuzumab and 48 hours lapatinib) and differential gene expression analyses were performed on each treatment group relative to untreated cardiomyocytes. Results: 517 and 1,358 genes were differentially expressed, p<0.05, respectively in cardiomyocytes treated with trastuzumab and lapatinib. Gene ontology analyses revealed in cardiomyocytes treated with trastuzumab, significant down-regulation of genes involved in small molecule metabolism (p=3.22x10-9) and cholesterol (p=0.01) and sterol (p=0.03) processing. Conclusions: Our study suggests dysregulation of cardiac gene expression and metabolism as key elements of ERBB2 signaling that could potentially be early biomarkers of cardiotoxicity.
2017-03-08 | GSE91383 | GEO
Project description:Glucose-lowering drugs sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of serious heart failure events, regardless of diabetes status, but the underling mechanism of this cardioprotective benefit is unknown. Here, we performed RNA-seq screening in cardiomyocytes to determine the potential cardioprotective mechanism of empagliflozin (EMPA).
2022-12-12 | GSE200598 | GEO
Project description:β-Catenin signaling pathway regulates cardiomyocytes proliferation and differentiation, though its involvement in metabolic regulation of cardiomyocytes remains unknown. We used one-day-old mice with cardiac-specific knockout of β-catenin and neonatal rat ventricular myocytes treated with β-catenin inhibitor to investigate the role of β-catenin metabolism regulation in perinatal cardiomyocytes. Transcriptomics of perinatal β-catenin-ablated hearts revealed a dramatic shift in the expression of genes involved in metabolic processes. Further analysis indicated an inhibition of lipolysis and glycolysis in both in vitro and in vivo models. Finally, we showed that β-catenin deficiency leads to mitochondria dysfunction via the downregulation of Sirt1/PGC-1α pathway. We conclude that cardiac-specific β-catenin ablation disrupts the energy substrate shift that is essential for postnatal heart maturation, leading to perinatal lethality of homozygous β-catenin knockout mice.
2021-08-31 | GSE153995 | GEO
Project description:Analysis of human iPS-derived cardiomyocytes exposed to glucose, endothelin-1 and cortisol in vitro. Treatment produces a surrogate diabetic cardiomyopathic phenotype. Results provide insight into the pathways regulated by the treatment in the cardiomyocyte.
2014-10-10 | GSE62203 | GEO